Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of <i>DYRK1A</i>.

bioRxiv : the preprint server for biology·2023
Same author

Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2023
Same author

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".

Blood cancer journal·2022
Same author

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.

Blood cancer journal·2022
Same author

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients.

Blood cancer journal·2018
Same author

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.

Blood cancer journal·2017

Related Experiment Video

Updated: Jul 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Imatinib for systemic mast-cell disease.

A Pardanani1, M Elliott, T Reeder

  • 1Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.

Lancet (London, England)
|August 23, 2003
PubMed
Summary

Imatinib effectively treats systemic mast-cell disease by targeting c-kit. Fifty percent of patients showed significant response, with some achieving complete remission, highlighting imatinib

More Related Videos

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
09:39

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish

Published on: December 26, 2014

Generation of Induced Pluripotent Stem Cell-Derived iTenocytes via Combined Scleraxis Overexpression and 2D Uniaxial Tension
04:48

Generation of Induced Pluripotent Stem Cell-Derived iTenocytes via Combined Scleraxis Overexpression and 2D Uniaxial Tension

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jul 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
09:39

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish

Published on: December 26, 2014

Generation of Induced Pluripotent Stem Cell-Derived iTenocytes via Combined Scleraxis Overexpression and 2D Uniaxial Tension
04:48

Generation of Induced Pluripotent Stem Cell-Derived iTenocytes via Combined Scleraxis Overexpression and 2D Uniaxial Tension

Published on: March 1, 2024

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Systemic mast-cell disease (SMCD) is a rare condition often driven by mutations in the c-kit proto-oncogene.
  • Imatinib is a tyrosine kinase inhibitor known to target c-kit and has shown efficacy in certain malignancies.

Purpose of the Study:

  • To evaluate the efficacy and safety of imatinib in adult patients with symptomatic systemic mast-cell disease.
  • To assess the response rates and clinical outcomes in patients treated with imatinib at different doses.

Main Methods:

  • A prospective study involving 12 adult patients with symptomatic SMCD.
  • Patients received imatinib at daily doses of 100 mg or 400 mg.
  • Response was assessed by clinical, histological, and hematological parameters, including mast cell cytoreduction and eosinophilia.

Main Results:

  • Fifty percent (5 out of 10 assessable patients) demonstrated a measurable response to imatinib.
  • Four patients achieved significant mast cell cytoreduction, and two achieved complete clinical and histological remission.
  • Three out of five patients with eosinophilia achieved complete clinical and hematological remission. Non-responders possessed the c-kit D816V mutation.

Conclusions:

  • Imatinib demonstrates significant clinical activity in systemic mast-cell disease.
  • The drug appears effective against wild-type c-kit-driven disease, with limited efficacy in patients harboring the c-kit D816V mutation.
  • Imatinib may inhibit the growth-promoting role of wild-type c-kit or target other oncogenic kinases in SMCD.